Baseline characteristics of patients included in the matched* study cohorts
| Characteristic | Group; no. (%) of patients† | |
|---|---|---|
| DOAC n = 128 273 | Warfarin n = 128 273 | |
| Age, mean ± SE, yr | 75.3 ± 0.9 | 75.3 ± 0.9 |
| Sex, male | 67 159 (52.4) | 67 159 (52.4) |
| Year of base cohort entry | ||
| 2009–2010 | 259 (0.2) | 1222 (1.0) |
| 2011–2012 | 27 332 (21.3) | 26 356 (20.5) |
| 2013–2014 | 51 343 (40.0) | 55 451 (43.2) |
| 2015–2016 | 49 339 (38.5) | 45 244 (35.3) |
| DOAC received at study entry | ||
| Dabigatran | 40 503 (31.6) | – |
| 110 mg twice daily | 20 857 (51.5) | – |
| 150 mg twice daily | 18 134 (44.8) | – |
| Other | 1512 (3.7) | – |
| Rivaroxaban | 49 498 (38.6) | – |
| 15 mg once daily | 14 981 (30.3) | – |
| 20 mg once daily | 31 706 (64.1) | – |
| Other | 2811 (5.7) | – |
| Apixaban | 38 272 (29.8) | – |
| 2.5 mg twice daily | 13 452 (35.1) | – |
| 5 mg twice daily | 23 465 (61.3) | – |
| Other | 1355 (3.5) | – |
| Treatment switches | 7360 (5.7) | 44 950 (35.0) |
| Length of follow-up, mean ± SE, d | 715 ± 50.20 | 762 ± 93.3 |
| Medical diagnoses | ||
| Congestive heart failure | 29 970 (23.4) | 29 740 (23.2) |
| Hypertension | 99 835 (77.8) | 99 430 (77.5) |
| Diabetes | 38 801 (30.2) | 38 931 (30.4) |
| Stroke | 22 274 (17.4) | 22 178 (17.3) |
| Transient ischemic attack | 6557 (5.1) | 6354 (5.0) |
| Chronic kidney injury | 11 423 (8.9) | 12 391 (9.7) |
| Acute kidney injury | 3843 (3.0) | 4961 (3.9) |
| Liver disease | 4882 (3.8) | 5196 (4.0) |
| Cancer | 13 624 (10.6) | 14 186 (11.1) |
| Chronic obstructive pulmonary disease | 34 308 (26.7) | 34 553 (26.9) |
| Coronary atherosclerosis | 56 766 (44.2) | 54 435 (42.4) |
| Myocardial infarction | 17 587 (13.7) | 17 714 (13.8) |
| Peripheral vascular disease | 15 997 (12.5) | 16 526 (12.9) |
| Prior bleeding | 8115 (6.3) | 8912 (6.9) |
| Dementia | 12 691 (9.9) | 12 758 (9.9) |
| CHADS score, mean ± SE | 2.41 ± 0.43 | 2.4 ± 0.41 |